Nimbex

(Cisatracurium)

ApprovedSmall molecule

Cisatracurium is a muscle relaxant used during anesthesia to paralyze muscles temporarily, making it easier for doctors to perform surgery and manage a patient's breathing during procedures.[2] Nimbex is currently approved and in use across 12 indications[4].[1]

Nimbex is one of 160 small molecule programs targeting Muscle spasm. It is currently in Approved.

Indications

Total Trials

Active Trials

159

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Muscle SpasmActive, not recruiting

Cardiac ArrestActive, not recruiting

Respiratory FailureActive, not recruiting

Subdural HemorrhageActive, not recruiting

HematomaActive, not recruiting

Intracranial Subdural HematomaActive, not recruiting

Urinary System DiseaseActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Acute Respiratory Distress SyndromeActive, not recruiting

MyalgiaActive, not recruiting

Muscle SpasmApproved

Active, not recruiting

Cardiac ArrestPreclinical

Active, not recruiting

Respiratory FailurePreclinical

Active, not recruiting

Subdural HemorrhagePreclinical

Active, not recruiting

HematomaPreclinical

Active, not recruiting

Intracranial Subdural HematomaPreclinical

Active, not recruiting

Urinary System DiseasePreclinical

Active, not recruiting

Chronic Kidney DiseaseApproved

Active, not recruiting

Acute Respiratory Distress SyndromePreclinical

Active, not recruiting

MyalgiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Nimbex

AbbVie

Approved

1 2

Aranesp

Amgen

Preclinical

40 3

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

16 4

Flomax

Epoetin Beta

5 6

Genotropin

EMD Serono

Preclinical

1 7

PROCRIT

WWim Janssens

Preclinical

1 8

Nitrostat

VViatris Specialty LLC

Singulair

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

N/ARecruiting

Respiratory Failure

NCT04524585

Q3 2027

Post-ApprovalRecruiting

Chronic Kidney Disease

NCT07203287

Clinical

Trials by Indication[1]

Neuromuscular Blocking Agents2 trials

Systematic Early Use of Neuromuscular Blocking Agents in ARDS Patients

Completed·AAssistance Publique Hopitaux De Marseille·Phase 4·NCT00299650·340 enrolled

Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals

Completed·JJakob Louis Thomsen··NCT02914119·30,430 enrolled

Elderly Patients1 trial

Etomidate to Improve Outcome in Elderly Patients

Completed·ZZhihong LU·N/A·NCT02910206·1,917 enrolled

Respiratory Failure1 trial

Partial Neuromuscular Blockade in Acute Hypoxemic Respiratory Failure

Recruiting·UUniversity Health Network, Toronto·N/A·NCT04524585·23 enrolled

Hematoma1 trial

Scalp Block Versus General Anesthesia in Patients Undergoing Evacuation of Subdural Hematoma Via Burr Hole

Recruiting·SSohag University·N/A·NCT07143799·80 enrolled

Chronic Kidney Disease1 trial

Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease

Recruiting·TThe University of Texas Medical Branch, Galveston·Phase 4·NCT07203287·490 enrolled

24 more indications

Neuromuscular Blockade1 trial

Depth of Neuromuscular Blockade and the Perioperative Conditions in Laparoscopic Surgery in Pediatric Population

Completed·—·N/A·NCT02546843·66 enrolled

Intravenous Lidocaine1 trial

Effects of Intravenous Lidocaine Associated With Magnesium Sulfate on the Cisatracurium-Induced Neuromuscular Block

Completed·UUniversity of Sao Paulo·Phase 4·NCT02483611·48 enrolled

Laparoscopic Cholecystectomy1 trial

Evaluation of Residual Neuromuscular Blockade and of Late Recurarization in the Post Anesthesia Care Unit in Patients Undergoing Videolaparoscopic Cholecystectomy

Completed·FFederal University of Minas Gerais··NCT03831815·85 enrolled

Target Controlled Infusion of Propofol1 trial

THe Comparison of Target Controlled Infusion of Propofol or Etomidate at General Anesthesia in Geriatric Patients

Unknown status·SSecond Affiliated Hospital of Xi'an Jiaotong University·Phase 4·NCT02111265·90 enrolled

Myalgia1 trial

Effects of Cisatracurium on Succinylcholine-induced Fasciculations and Myalgia

Completed·—·Phase 3·NCT02481193·90 enrolled

Propofol1 trial

Gender and PK-PD of Propofol and Cisatracurium

Completed·MMedical University of Graz··NCT02588118·120 enrolled

Sedation1 trial

The Efficacy of P0.1-guided Sedation Protocol in Critically Ill Patients Receiving Invasive Mechanical Ventilation: A Randomized Controlled Trial

Recruiting·SSiriraj Hospital·N/A·NCT06203405·214 enrolled

Tics1 trial

The Study of Pharmacokinetics and Pharmacodynamics of Cisatracurium

Completed·MMahidol University·Phase 4·NCT03337373·10 enrolled

Laryngeal Mask Airway1 trial

Muscle Relaxants and Laryngeal Local Anesthetics for Laryngeal Mask Airway Insertion Decreasing Propofol in Elderly

Completed·—·N/A·NCT05310110·96 enrolled

Analgesia1 trial

The Efficacy and Optimal Dose of Sufentanil in Patient Controlled Analgesia After Moderate Surgery

Unknown status·SSecond Affiliated Hospital of Xi'an Jiaotong University·Phase 4·NCT02503826·60 enrolled

Prevention1 trial

Median Effective Dose of Cisatracurium for the Prevention of Fasciculation Caused by the Injection of Succinylcholine

Unknown status·YYangzhou University·N/A·NCT05760976·90 enrolled

Intraocular Pressure1 trial

Effect of Cisatracurium Versus Atracurium on Intraocular Pressure in Patients Underwent General Anesthesia

Completed·IIsfahan University of Medical Sciences·Phase 2·NCT01273831·90 enrolled

Anesthesia1 trial

Is it Possible to Replace Fentanyl in Anesthesia for Minor Procedures?

Completed·—·N/A·NCT03806374·120 enrolled

Laparoscopic1 trial

Effect of Laparoscopic Operation on Rocuronium and Cisatracurium: Pharmacokinetic and Pharmacodynamic Analysis

Completed·FFudan University·Phase 4·NCT02194855·100 enrolled

Muscle Relaxation1 trial

Pediatric Elective Intubation With and Without Muscle Relaxation Utilizing the Shikani Optical Stylet

Terminated·RRady Children's Hospital, San Diego·N/A·NCT00912990·34 enrolled

LCH1 trial

Effects of Cisatracurium on Sccinylcholine-induced Fasciculations

Completed·ZZhuan Zhang·Phase 3·NCT02502032·87 enrolled

General Anaesthesia1 trial

Comparison Between Cisatracurium and Rocuronium in Terms of Recovery of the Muscular Strength in the Postoperative Phase After Surgery and General Anaesthesia

Completed·AAzienda Ospedaliera di Padova·Phase 4·NCT01651572·120 enrolled

Observational Study1 trial

An Observational Study of Cisatracurium 0.15 mg/kg in Young and Elderly (≥ 80 Years) Patients.

Completed·MMatias Vested··NCT04921735·60 enrolled

Acute Respiratory Distress Syndrome1 trial

Effect of Different Depths of Neuromuscular Blockade on Respiratory Mechanics in Patients With Moderate-severe Acute Respiratory Distress Syndrome

Recruiting·SSoutheast University, China·N/A·NCT06514209·20 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of HRS-9190 Compared to Cisatracurium for Continuous Intravenous Infusion in Adults

Not yet recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT07446309·60 enrolled

Cardiac Arrest1 trial

When Cooling a Patient After Cardiac Arrest, Does Use of a Neuromuscular Blocking Agent Make Your Job Easier?

Unknown status·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's··NCT02033733·400 enrolled

Neostigmine1 trial

Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine in Obese Participants (MK-8616-104)

Withdrawn· Merck & Co. logo

Merck & Co.·Phase 4·NCT02410590

Complication1 trial

Effect of Neuromuscular Blockade on Pulmonary Complications in Elective Cardiac Surgery

Completed·UUniversity of Chicago·Phase 4·NCT02635542·100 enrolled

Unspecified1 trial

A Study of Residual Curarization Incidence in China

Unknown status·PPeking University First Hospital·Phase 4·NCT01690338·6,090 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 15, 1995

NIMBEX

NDA NDA020551

Sources

References

[1]
ClinicalTrials.gov — 30 trial records for Cisatracurium. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Nimbex drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Cisatracurium compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Cisatracurium. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020551). U.S. Food & Drug Administration.
[6]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Muscle-Type Nicotinic Acetylcholine Receptor Antagonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AbbVie

Nimbex

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Trials by Indication[1]

Neuromuscular Blocking Agents2 trials

Elderly Patients1 trial

Respiratory Failure1 trial

Hematoma1 trial

Chronic Kidney Disease1 trial

Neuromuscular Blockade1 trial

Intravenous Lidocaine1 trial

Laparoscopic Cholecystectomy1 trial

Target Controlled Infusion of Propofol1 trial

Myalgia1 trial

Propofol1 trial

Sedation1 trial

Tics1 trial

Laryngeal Mask Airway1 trial

Analgesia1 trial

Prevention1 trial

Intraocular Pressure1 trial

Anesthesia1 trial

Laparoscopic1 trial

Muscle Relaxation1 trial

LCH1 trial

General Anaesthesia1 trial

Observational Study1 trial

Acute Respiratory Distress Syndrome1 trial

Safety and Efficacy1 trial

Cardiac Arrest1 trial

Neostigmine1 trial

Complication1 trial

Unspecified1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News